PE20181400A1 - Formulacion farmaceutica acuosa del anticuerpo anti-pd-l1 avelumab - Google Patents
Formulacion farmaceutica acuosa del anticuerpo anti-pd-l1 avelumabInfo
- Publication number
- PE20181400A1 PE20181400A1 PE2018001077A PE2018001077A PE20181400A1 PE 20181400 A1 PE20181400 A1 PE 20181400A1 PE 2018001077 A PE2018001077 A PE 2018001077A PE 2018001077 A PE2018001077 A PE 2018001077A PE 20181400 A1 PE20181400 A1 PE 20181400A1
- Authority
- PE
- Peru
- Prior art keywords
- concentration
- aqueous pharmaceutical
- formulation
- sequence
- pharmaceutical formulation
- Prior art date
Links
- 229950002916 avelumab Drugs 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000009472 formulation Methods 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 abstract 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 abstract 1
- KWTQSFXGGICVPE-WCCKRBBISA-N Arginine hydrochloride Chemical compound Cl.OC(=O)[C@@H](N)CCCN=C(N)N KWTQSFXGGICVPE-WCCKRBBISA-N 0.000 abstract 1
- 206010005003 Bladder cancer Diseases 0.000 abstract 1
- 201000009030 Carcinoma Diseases 0.000 abstract 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 abstract 1
- 229920001213 Polysorbate 20 Polymers 0.000 abstract 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 abstract 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 235000013922 glutamic acid Nutrition 0.000 abstract 1
- 239000004220 glutamic acid Substances 0.000 abstract 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 abstract 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 abstract 1
- 229940068977 polysorbate 20 Drugs 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
- 201000005112 urinary bladder cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
SE REFIERE A UNA FORMULACION DE ANTICUERPO FARMACEUTICA ACUOSA QUE COMPRENDE: A) AVELUMAB EN UNA CONCENTRACION DE 1 MG/ML A 30 MG/ML CUYA SECUENCIA DE CADENA PESADA ES LA SEC ID NO: 1 O SEC ID NO: 2, Y LA SECUENCIA DE CADENA LIGERA ES LA SEC ID NO: 3; B) ACETATO O HISTIDINA EN UNA CONCENTRACION DE 5 mM A 15 mM COMO AGENTE AMORTIGUADOR; C) D-MANITOL O TREHALOSA EN UNA CONCENTRACION DE 240 mM A 320 mM, O UNA COMBINACION DE ARGININA HCl EN UNA CONCENTRACION DE 50 A 150 mM Y ACIDO GLUTAMICO EN UNA CONCENTRACION DE 25 mM A 75 mM COMO ESTABILIZANTE; y D) POLOXAMERO 188 O POLISORBATO 20 EN UNA CONCENTRACION DE 0,25 MG/ML A 0,75 MG/ML COMO SURFACTANTE; DONDE LA FORMULACION TIENE UN PH DE 5 A 6. DICHA FORMULACION ES UTIL PARA EL TRATAMIENTO DEL CANCER PULMONAR DE CELULAS NO PEQUENAS, CARCINOMA UROTELIAL, CANCER DE VEJIGA
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15198233 | 2015-12-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20181400A1 true PE20181400A1 (es) | 2018-09-07 |
Family
ID=54838201
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2018001077A PE20181400A1 (es) | 2015-12-07 | 2016-12-05 | Formulacion farmaceutica acuosa del anticuerpo anti-pd-l1 avelumab |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US11058769B2 (es) |
| EP (2) | EP3747466A1 (es) |
| JP (1) | JP6925337B2 (es) |
| KR (1) | KR102697026B1 (es) |
| CN (1) | CN108367072B (es) |
| AR (1) | AR107014A1 (es) |
| AU (1) | AU2016368099C1 (es) |
| BR (1) | BR112018010211A2 (es) |
| CA (1) | CA3007481C (es) |
| CL (1) | CL2018001488A1 (es) |
| CO (1) | CO2018005525A2 (es) |
| CY (1) | CY1123358T1 (es) |
| DK (1) | DK3386541T3 (es) |
| EA (1) | EA201891339A1 (es) |
| ES (1) | ES2823279T3 (es) |
| HR (1) | HRP20201573T1 (es) |
| HU (1) | HUE050811T2 (es) |
| IL (1) | IL259563B (es) |
| LT (1) | LT3386541T (es) |
| MX (1) | MX389289B (es) |
| MY (1) | MY195681A (es) |
| NZ (1) | NZ743964A (es) |
| PE (1) | PE20181400A1 (es) |
| PH (1) | PH12018500894A1 (es) |
| PL (1) | PL3386541T3 (es) |
| PT (1) | PT3386541T (es) |
| RS (1) | RS61029B1 (es) |
| SA (1) | SA518391743B1 (es) |
| SG (1) | SG11201804758QA (es) |
| SI (1) | SI3386541T1 (es) |
| SM (1) | SMT202000497T1 (es) |
| TW (1) | TWI630917B (es) |
| UA (1) | UA123270C2 (es) |
| WO (1) | WO2017097407A1 (es) |
| ZA (1) | ZA201804534B (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202000561T1 (it) | 2011-11-28 | 2021-01-05 | Merck Patent Gmbh | Anticorpi anti-pd-l1 e usi relativi |
| US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| KR20220126813A (ko) | 2014-03-14 | 2022-09-16 | 노파르티스 아게 | Lag-3에 대한 항체 분자 및 그의 용도 |
| EP3925622A1 (en) | 2014-09-13 | 2021-12-22 | Novartis AG | Combination therapies |
| EP3206711B1 (en) | 2014-10-14 | 2023-05-31 | Novartis AG | Antibody molecules to pd-l1 and uses thereof |
| BR112017019559B1 (pt) | 2015-03-13 | 2020-08-04 | Cytomx Therapeutics, Inc | Anticorpos anti-pdl1, anticorpos anti-pdl1 ativáveis, e métodos de uso destes |
| PE20181400A1 (es) | 2015-12-07 | 2018-09-07 | Merck Patent Gmbh | Formulacion farmaceutica acuosa del anticuerpo anti-pd-l1 avelumab |
| WO2017215590A1 (en) | 2016-06-13 | 2017-12-21 | I-Mab | Anti-pd-l1 antibodies and uses thereof |
| MX2019003755A (es) | 2016-10-06 | 2019-08-12 | Pfizer | Regimen de dosificacion de avelumab para el tratamiento de cancer. |
| SG11201908091QA (en) * | 2017-03-06 | 2019-10-30 | Merck Patent Gmbh | Aqueous anti-pd-l1 antibody formulation |
| AU2018278327B2 (en) | 2017-06-01 | 2023-03-16 | Cytomx Therapeutics, Inc. | Activatable anti-pdl1 antibodies and methods of use thereof |
| EP3705134A4 (en) * | 2017-11-02 | 2021-07-28 | Nanjing Shunxin Pharmaceutical Co., Ltd. | PHARMACEUTICAL COMPOSITION CONTAINING A HUMANIZED MONOCLONAL ANTIBODY ANTI-PD-L1 |
| AU2018388301B2 (en) * | 2017-12-22 | 2022-02-17 | Samsung Bioepis Co., Ltd. | Liquid composition comprising VEGF antagonist |
| JP2021508478A (ja) * | 2017-12-28 | 2021-03-11 | ユリウス・マクシミリアンス−ウニヴェルジテート・ヴュルツブルクＪｕｌｉｕｓ Ｍａｘｉｍｉｌｉａｎｓ−Ｕｎｉｖｅｒｓｉｔａｅｔ Ｗｕｅｒｚｂｕｒｇ | ＦｃγＲ非依存性アゴニスト活性がある腫瘍壊死因子（ＴＮＦ）受容体スーパーファミリー（ＴＮＦＲＳＦ）受容体活性化抗体融合タンパク質（ＦｃγＲ非依存性アゴニスト活性があるＴＮＦＲＳＦ受容体活性化抗体融合タンパク質；ＴＲＡＡＦＦＩＡＡ） |
| US11034771B2 (en) | 2018-07-25 | 2021-06-15 | I-Mab Biopharma Us Limited | Anti-CD73 anti-PD-L1 bispecific antibodies |
| WO2020060183A1 (ko) * | 2018-09-18 | 2020-03-26 | 삼성바이오에피스 주식회사 | 트라스투주맙 항체 안정화 액체 제제 |
| WO2020108497A1 (zh) * | 2018-11-29 | 2020-06-04 | 和铂医药（香港）有限公司 | 一种抗pd-l1抗体制剂 |
| SG11202108627SA (en) | 2019-02-18 | 2021-09-29 | Lilly Co Eli | Therapeutic antibody formulation |
| AU2020304112A1 (en) * | 2019-06-25 | 2022-01-27 | Innovent Biologics (Suzhou) Co., Ltd. | Formulations containing anti-CD47/PD-L1 bispecific antibody and preparation method therefor and use thereof |
| CN111420049A (zh) * | 2019-08-22 | 2020-07-17 | Biocad股份公司 | 抗-pd1抗体prolgolimab的水性药物组合物及其应用 |
| US12121565B2 (en) | 2019-09-13 | 2024-10-22 | Duke University | Methods of treatment of specific cancers with NLRP3 inhibitors and anti-PD1/PD-L1 antibodies |
| US12380963B2 (en) | 2019-10-14 | 2025-08-05 | The Medical College Of Wisconsin, Inc. | Gene expression signature of hyperprogressive disease (HPD) in patients after anti-PD-1 immunotherapy |
| EP4055153A4 (en) | 2019-11-04 | 2024-02-14 | Duke University | TREATMENT OF PRIMARY AND METASTASIC CANCER |
| JP2023506629A (ja) * | 2019-12-13 | 2023-02-17 | サムスン バイオエピス カンパニー リミテッド | 安定した抗ｐｄ－１抗体の薬剤学的製剤 |
| US20230059341A1 (en) * | 2019-12-18 | 2023-02-23 | Tesaro, Inc. | Biopharmaceutical compositions and related methods |
| KR102683876B1 (ko) * | 2020-11-11 | 2024-07-11 | 가톨릭대학교 산학협력단 | 표적 치료제의 치료 효과 증진을 위한 항체 기반 컨쥬게이트 |
| KR20240043747A (ko) | 2021-07-02 | 2024-04-03 | 예일 유니버시티 | 암을 치료하기 위한 조성물 및 방법 |
| US20250127917A1 (en) | 2021-08-31 | 2025-04-24 | Yale University | Compositions and methods for treating cancers |
| WO2024160721A1 (en) | 2023-01-30 | 2024-08-08 | Kymab Limited | Antibodies |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040033228A1 (en) * | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| PT1934236E (pt) | 2005-09-02 | 2012-12-26 | Glycomimetics Inc | Inibidores de pan-selectina heterobifuncionais |
| EP1962886B2 (en) | 2005-12-20 | 2022-02-23 | Bristol-Myers Squibb Company | Stable protein formulations |
| WO2009126556A1 (en) | 2008-04-08 | 2009-10-15 | Glycomimetics, Inc. | Pan-selectin inhibitor with enhanced pharmacokinetic activity |
| SMT202400136T1 (it) * | 2008-12-09 | 2024-05-14 | Hoffmann La Roche | Anticorpi anti-pd-l1 e loro uso per potenziare la funzione dei linfociti t |
| EP2196476A1 (en) * | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
| KR20120110175A (ko) * | 2009-12-29 | 2012-10-09 | 에프. 호프만-라 로슈 아게 | 항체 제제 |
| US8921328B2 (en) | 2010-09-14 | 2014-12-30 | Glycomimetics, Inc. | E-selectin antagonists |
| RS57492B1 (sr) * | 2011-03-31 | 2018-10-31 | Merck Sharp & Dohme | Stabilne formulacije antitela za humani receptor programirane smrti pd-1 i srodni tretmani |
| SMT202000561T1 (it) * | 2011-11-28 | 2021-01-05 | Merck Patent Gmbh | Anticorpi anti-pd-l1 e usi relativi |
| SG11201403792TA (en) | 2012-01-23 | 2014-10-30 | Regeneron Pharma | Stabilized formulations containing anti-ang2 antibodies |
| US9216219B2 (en) * | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
| EA201991715A1 (ru) | 2013-09-27 | 2020-03-31 | Дженентек, Инк. | Композиции, содержащие антитело к pdl1 |
| AU2014337263B2 (en) * | 2013-10-16 | 2019-12-12 | Outlook Therapeutics, Inc. | Buffer formulations for enhanced antibody stability |
| BR112016026559A8 (pt) * | 2014-05-15 | 2021-07-13 | Bristol Myers Squibb Co | uso de um anticorpo anti-pd-1 e outro agente anticâncer em combinação com quimioterapia dupla com base em platina (pt-dc) e kit |
| CN105085680A (zh) * | 2014-05-23 | 2015-11-25 | 复旦大学 | 人源化抗PD-1及c-MET双特异性抗体及其制备方法和应用 |
| EP4279087A3 (en) | 2015-02-26 | 2024-01-31 | Merck Patent GmbH | Pd-1 / pd-l1 inhibitors for the treatment of cancer |
| TW201705955A (zh) | 2015-05-14 | 2017-02-16 | 輝瑞大藥廠 | 包含吡咯啶－２，５－二酮ｉｄｏ１抑制劑及抗－ｐｄ１／抗－ｐｄ－ｌ１抗體之組合療法 |
| JP2018518483A (ja) | 2015-06-08 | 2018-07-12 | ジェネンテック， インコーポレイテッド | 抗ｏｘ４０抗体及びｐｄ−１軸結合アンタゴニストを使用して癌を治療する方法 |
| IL256245B (en) | 2015-06-16 | 2022-09-01 | Merck Patent Gmbh | Pd-l1 antagonist combination treatments |
| CA3000386A1 (en) | 2015-09-30 | 2017-04-06 | Merck Patent Gmbh | Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer |
| PE20181400A1 (es) | 2015-12-07 | 2018-09-07 | Merck Patent Gmbh | Formulacion farmaceutica acuosa del anticuerpo anti-pd-l1 avelumab |
| SG11201908091QA (en) | 2017-03-06 | 2019-10-30 | Merck Patent Gmbh | Aqueous anti-pd-l1 antibody formulation |
-
2016
- 2016-12-05 PE PE2018001077A patent/PE20181400A1/es unknown
- 2016-12-05 HR HRP20201573TT patent/HRP20201573T1/hr unknown
- 2016-12-05 BR BR112018010211A patent/BR112018010211A2/pt active Search and Examination
- 2016-12-05 CN CN201680071740.1A patent/CN108367072B/zh active Active
- 2016-12-05 US US16/060,319 patent/US11058769B2/en active Active
- 2016-12-05 EA EA201891339A patent/EA201891339A1/ru unknown
- 2016-12-05 SI SI201630940T patent/SI3386541T1/sl unknown
- 2016-12-05 ES ES16818985T patent/ES2823279T3/es active Active
- 2016-12-05 PL PL16818985T patent/PL3386541T3/pl unknown
- 2016-12-05 AU AU2016368099A patent/AU2016368099C1/en active Active
- 2016-12-05 SG SG11201804758QA patent/SG11201804758QA/en unknown
- 2016-12-05 CA CA3007481A patent/CA3007481C/en active Active
- 2016-12-05 EP EP20184113.7A patent/EP3747466A1/en not_active Withdrawn
- 2016-12-05 EP EP16818985.0A patent/EP3386541B1/en active Active
- 2016-12-05 MX MX2018006875A patent/MX389289B/es unknown
- 2016-12-05 NZ NZ743964A patent/NZ743964A/en unknown
- 2016-12-05 UA UAA201807363A patent/UA123270C2/uk unknown
- 2016-12-05 MY MYPI2018702171A patent/MY195681A/en unknown
- 2016-12-05 SM SM20200497T patent/SMT202000497T1/it unknown
- 2016-12-05 JP JP2018529213A patent/JP6925337B2/ja active Active
- 2016-12-05 KR KR1020187019480A patent/KR102697026B1/ko active Active
- 2016-12-05 PT PT168189850T patent/PT3386541T/pt unknown
- 2016-12-05 HU HUE16818985A patent/HUE050811T2/hu unknown
- 2016-12-05 DK DK16818985.0T patent/DK3386541T3/da active
- 2016-12-05 LT LTEP16818985.0T patent/LT3386541T/lt unknown
- 2016-12-05 WO PCT/EP2016/002040 patent/WO2017097407A1/en not_active Ceased
- 2016-12-05 RS RS20201201A patent/RS61029B1/sr unknown
- 2016-12-06 TW TW105140288A patent/TWI630917B/zh active
- 2016-12-07 AR ARP160103760A patent/AR107014A1/es not_active Application Discontinuation
-
2018
- 2018-04-26 PH PH12018500894A patent/PH12018500894A1/en unknown
- 2018-05-23 IL IL259563A patent/IL259563B/en active IP Right Grant
- 2018-05-25 CO CONC2018/0005525A patent/CO2018005525A2/es unknown
- 2018-06-04 CL CL2018001488A patent/CL2018001488A1/es unknown
- 2018-06-06 SA SA518391743A patent/SA518391743B1/ar unknown
- 2018-07-06 ZA ZA201804534A patent/ZA201804534B/en unknown
-
2020
- 2020-09-24 CY CY20201100904T patent/CY1123358T1/el unknown
- 2020-12-09 US US17/116,587 patent/US20210100903A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20181400A1 (es) | Formulacion farmaceutica acuosa del anticuerpo anti-pd-l1 avelumab | |
| AR122746A2 (es) | Una formulación farmacéutica líquida estable de anticuerpo | |
| PE20170780A1 (es) | Formulacion estable de proteina en solucion que contiene una alta concentracion de un anticuerpo anti-vegf | |
| PE20181365A1 (es) | Formulaciones subcutaneas de anticuerpos anti-cd38 y sus usos | |
| UA122478C2 (uk) | Водна фармацевтична композиція, яка містить моноклональне антитіло до pd-l1 | |
| PE20190405A1 (es) | FORMULACION PARA ANTICUERPO ANTI-alfa4beta7 | |
| PE20170665A1 (es) | Anticuerpos anti-tau humanizados | |
| MX2023001319A (es) | Polipeptidos condicionalmente activos. | |
| CL2019002190A1 (es) | Reducción de la viscosidad de formulaciones farmacéuticas que comprende una proteína terapéutica a una concentración de al menos 70 mg/ml, donde la proteína terapéutica no es un anticuerpo (divisional solicitud 201700984) | |
| MX2017003121A (es) | Formulaciones de anticuerpos. | |
| EA201490804A1 (ru) | Препараты этанерцепта, стабилизированные хлоридом натрия | |
| EA201790378A1 (ru) | Заключенное в липосому аффинное лекарственное средство | |
| EA201692301A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| MX2015015152A (es) | Formulaciones de anticuerpos biespecificos anti-il-4/anti-il-13. | |
| MX391216B (es) | Composicion farmaceutica que comprende un vector adenoviral. | |
| BR112016008576A2 (pt) | Formulações aquosas estáveis de anticorpos e forma farmacêutica de dosagem unitária | |
| PE20160012A1 (es) | Tratamiento de enfermedades miopaticas y neurogenerativas por agregacion de proteina mediante administracion parenteral | |
| AR098168A1 (es) | Formulación estable de insulina glulisina | |
| BR112019011769A2 (pt) | composição de anticorpo anti-c5 aquosa estável | |
| UY36542A (es) | Formulaciones farmacéuticas para anticuerpos anti-tnf-alfa | |
| AR103243A1 (es) | Recipiente precargado con toxina botulínica | |
| EA201992832A1 (ru) | Подкожное введение adamts13 | |
| CO7270463A2 (es) | Composición farmacéutica acuosa que contiene un agente terapéutico biológico y guanidina o un derivado de la guanidina y una inyección que incluye la composición | |
| MX387451B (es) | Formulacion liquida que comprende un compuesto neutralizante de gm-csf. | |
| AR091530A1 (es) | Formulacion farmaceutica liquida de un anticuerpo y acetato |